• Durect Corp., of Cupertino, Calif., said top-line data from its Phase III BESST (Bupivacaine Effectiveness and Safety in SABER) study of Posidur in postoperative pain relief failed to reach statistical significance, though results trended positive for both pain reduction and reduction of supplemental opioid use in the first three days after surgery. The study enrolled a total of 305 patients undergoing a variety of general abdominal surgical procedures. Shares of Durect (NASDAQ:DRRX) plunged 34 percent, or 44 cents, to close Friday at 74 cents.